Skip to content

Pervasis, founded in 2003, was a clinical-stage company advancing new therapies to dramatically improve the outcomes of common vascular interventions, such as arteriovenous access, angioplasties, stents, and peripheral and coronary bypass grafts. Pervasis was acquired by Shire for $200M in 2012.

Latest News from Pervasis Therapeutics

Next